Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758966 · ClinicalTrials.gov registry record · Phase 2
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00758966 is a Phase 2 study that was terminated before completion, run by Orexigen Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT00758966, a Phase 2 study, was terminated before completion, sponsored by Orexigen Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
Interventions
- DRUG Fluoxetine 60 mg
- DRUG Naltrexone 32 mg and fluoxetine 60 mg
- DRUG Naltrexone SR 32 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758966
The ClinicalTrials.gov registry entry for NCT00758966 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluoxetine 60 mg is the first listed.
NCT00758966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00758966 about?
NCT00758966 is a clinical study titled "Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder". The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
What is the current status of trial NCT00758966?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00758966?
The interventions under investigation include: Fluoxetine 60 mg (DRUG), Naltrexone 32 mg and fluoxetine 60 mg (DRUG), Naltrexone SR 32 mg (DRUG).
Who is sponsoring clinical trial NCT00758966?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.